People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Platelet BioGenesis, Inc. | — | Other | Series B | $72.9M | $427.0M | 2016 |
Peter Erik Finn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Erik Finn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Finn | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Richard Murray | 1 | 5 |
| Mark McDade | 1 | 5 |
| Chidozie Ugwumba | 1 | 3 |
| Jonathan Thon | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Philip Reilly | 1 | 2 |
| Jonathan Erik Thon | 1 | 1 |
| Joseph Italiano | 1 | 1 |
| Sven Erik Karlsson | 1 | 1 |
| Sven Karlsson | 1 | 1 |
| Sam Rasty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.